Table 4.

Progression-Free Survival and Overall Survival by Tumor Grade and Residual Disease Status

Strata	n	Progression-Free Survival in Months (P<.001)*	Progression-Free Survival Adjusted HR (95% CI)	P†	Overall Survival in Months (P<.001)*	Overall Survival, Adjusted HR (95% CI)	P†
Low-grade serous   carcinoma,   nonmeasurable	47	33.22 (23.10–72.61)	Referent	—	96.89 (76.82–—)	Referent	—
High-grade serous   carcinoma,   nonmeasurable	358	26.84 (22.84–31.28)	1.06 (0.74–1.52)	.742	77.07 (67.48–   88.84)	1.32 (0.84–2.05)	.224
Low-grade serous   carcinoma,   measurable	142	14.11 (12.52–16.10)	2.28 (1.56–3.33)	<.001	42.02 (36.83–   53.19)	2.12 (1.33–3.38)	.002
High-grade serous   carcinoma,   measurable	1,405	14.39 (13.86–14.88)	1.75(1.24–2.46)	.002	37.68 (35.84–   39.39)	2.31 (1.50–3.55)	<.001

HR, hazard ratio; CI, confidence interval.

Data are median (range) unless otherwise specified.

^*Log-rank test for comparing survival distributions.

^†Wald test for individual predictors in the Cox model